Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-2
pubmed:dateCreated
1988-10-24
pubmed:abstractText
Nine healthy subjects, 19 patients with multiple myeloma (MM) and 21 patients with chronic uremia were given cefodizime (2 g i.v.) at 2 different timepoints either in the morning or in the evening for 5 to 7 consecutive days. The following immunological parameters were comparatively evaluated before and after cefodizime administration: rosette-forming cells (RFC%), T lymphocyte subpopulations, monocyte chemotaxis index (MCI) and granulocyte chemotaxis index (GCI). Independently of the time of drug administration, a circadian rhythm was clearly detected (90% CI) as regards RFC%, CD3, CD4, CD8, CD4/CD8 before and RFC%, CD3, CD4, CD8, GCI after therapy. In addition, in patients treated at 0800 cefodizime increased the MESOR of the MCI and, to a lesser extent, of the GCI. The chronoimmunomodulatory effects of cefodizime in patients with MM and chronic uremia are discussed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0390-0037
pubmed:author
pubmed:issnType
Print
pubmed:volume
15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
61-85
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:articleTitle
Toward a chronoimmunomodulation by cefodizime in multiple myeloma and chronic uremia.
pubmed:affiliation
Cattedra di Cronobiologia, Facoltà di Medicina e Chirurgia, Università degli Studi di Milano, Italy.
pubmed:publicationType
Journal Article